UK Clinical Trial Reforms: What the April 2026 Changes Really Mean for Industry

From 28 April 2026, the UK will implement the most significant overhaul of its clinical trials framework in over 20 years. Driven by the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, these changes are designed to modernise how trials are approved, conducted, and overseen, while maintaining the highest standards of patient safety and product quality.

While much of the conversation has focused on faster approvals and improved patient access, the reality is that these reforms go much deeper. They introduce meaningful changes across regulatory expectations, GMP alignment, manufacturing responsibilities, and trial delivery.

A More Agile and Risk-Based Regulatory Framework

At the heart of the reform is a move towards a more proportionate, risk-based system.

Sponsors will now have two main application routes: the existing combined review pathway, and a new “notifiable trial” route. For eligible low-risk trials, this can enable automatic approval within 14 days, significantly reducing timelines for trial initiation.

Beyond applications, oversight itself is becoming more dynamic. Sponsors are now expected to define the level of oversight based on risk, trial complexity, and critical-to-quality factors, rather than applying a fixed, one-size-fits-all model. This allows for greater flexibility, while still ensuring robust control where it matters most.

A Clear Expectation: Follow the Guidance

A key regulatory shift that should not be overlooked is the strengthened expectation around compliance with guidance.

Under the updated regulations, sponsors, investigators, and any delegated third parties must actively consider and follow all relevant guidance when designing and conducting clinical trials. This places greater responsibility on organisations to ensure they are not only aware of regulatory expectations, but are embedding them into their operational processes.

Importantly, this also extends to manufacturing sites named within clinical trial applications, reinforcing the need for alignment across the full supply chain.

GMP for IMPs: Alignment Without Additional Burden

From a manufacturing perspective, the updated regulations clarify how Good Manufacturing Practice (GMP) applies across the UK.

In Great Britain, GMP expectations continue to align with Commission Directive 2003/94/EC, while Northern Ireland follows Commission Delegated Regulation 2017/1569, supported by EU GMP Annex 13. Although the EU Clinical Trials Regulation is not directly applicable in Great Britain, the MHRA has maintained alignment with international standards, including PIC/S and EU expectations for Qualified Persons (QPs).

New UK-specific GMP guidance for investigational medicinal products (IMPs) is expected, aiming to provide clarity without introducing additional burden for manufacturers. For organisations, this reinforces the importance of maintaining robust, inspection-ready quality systems that align with both UK and international frameworks.

Manufacturing and QP Oversight: Increased Clarity, Especially for Radiopharmaceuticals

One of the more nuanced areas of the reform relates to radiopharmaceutical (RP) IMPs, particularly those used for diagnostic purposes.

The updated regulations introduce greater flexibility by allowing certain RP IMP manufacturing and assembly activities to take place at sites holding a Manufacturer’s Licence (MIA) or a Specials (MS) licence, rather than requiring a dedicated MIA (IMP) licence in all cases.

However, this flexibility does not remove the requirement for Qualified Person (QP) oversight. Final batch certification must still be performed by a QP at a MIA (IMP) licensed site, and clear technical agreements must be in place between all parties to define responsibilities and ensure quality oversight.

For example, in “cold kit” scenarios, a non-radioactive IMP may be QP-certified at a MIA (IMP) site before being radiolabelled at an MS-licensed facility. In these cases, no further QP certification is required post-radiolabelling, provided appropriate controls are in place.

In contrast, where full manufacture and radiolabelling occur together (such as with certain PET tracers), the QP retains full responsibility for certification, including oversight of any outsourced activities.

These changes provide operational flexibility, but also require clear governance, strong quality systems, and well-defined contractual arrangements.

Labelling, Safety and Transparency: Raising the Bar

The reforms also introduce updates across labelling, pharmacovigilance, and transparency requirements.

Labelling expectations are now clearly defined within the updated regulations, with additional guidance supporting implementation. While some flexibility is allowed (such as the inclusion of internal identification codes for artwork control), sponsors must ensure that labelling remains compliant and consistent across all trial materials.

On the safety side, reporting requirements are becoming more detailed. Development Safety Update Reports (DSURs) will need to include clearer analysis of safety signals, actions taken, and ongoing risk evaluation.

Transparency is another major focus. Clinical trials must be registered early, and results are expected to be published within defined timelines. These measures are intended to improve trust, accountability, and knowledge sharing across the research landscape.

Tackling the Patient Participation Challenge

Despite regulatory progress, patient participation remains one of the biggest barriers to clinical trial success. Currently, only around 3 percent of eligible patients take part in trials.

The new framework aims to address this by simplifying processes, enabling more flexible consent approaches (particularly for low-intervention trials), and making trials more accessible overall.

Increasing participation is not just beneficial for patients. It also has a direct impact on the UK’s attractiveness as a research destination and its ability to generate economic value through innovation.

Digital Transformation and Ongoing Support

To support implementation, the UK is investing in modernising its clinical trial infrastructure.

A new digital platform, “Plan and Manage Health and Care Research,” will gradually replace existing systems, improving how trials are submitted, reviewed, and managed. During the transition, organisations will need to navigate a hybrid approach, using existing systems alongside new processes.

Regulators have also committed to ongoing guidance, stakeholder engagement, and iterative updates, recognising that practical implementation will evolve over time.

What This Means for Industry

For sponsors, CROs, and manufacturing organisations, these reforms represent both an opportunity and a responsibility.

There is clear potential to accelerate trial timelines, improve operational efficiency, and expand research capability. However, this comes with increased expectations around risk-based thinking, documentation, training, and cross-functional alignment.

Now is the time to:

• Review and update SOPs in line with new regulatory expectations
• Assess GMP and QP oversight models, particularly for IMP supply chains
• Conduct labelling and pharmacovigilance gap analyses
• Ensure teams are trained and prepared for the new framework

The April 2026 reforms are more than just a regulatory update. They mark a shift towards a more agile, patient-centric, and innovation-driven clinical trial environment.

For those who prepare early and embed these changes effectively, there is a real opportunity to not only remain compliant, but to operate more efficiently and competitively within the evolving UK clinical research landscape.